Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334899 | 1.00 | ATM (0.59) | ATMACEMMEDPP4DPP8 | |
| SCHEMBL1334897 | 1.00 | ATM (0.59) | ATMACEMMEDPP4DPP8 | |
| SCHEMBL1336087 | 1.00 | ATM (0.59) | ATMACEMMEDPP4DPP8 | |
| SCHEMBL1334463 | 1.00 | ATM (0.59) | ATMACEMMEDPP4DPP8 | |
| SCHEMBL1334597 | 1.00 | ATM (0.59) | ATMACEMMEDPP4DPP8 | |
| SCHEMBL3721420 | 1.00 | ATM (0.59) | ATMACEMMEDPP4DPP8 | |
| SCHEMBL1335548 | 0.85 | ATM (0.45) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1336882 | 0.85 | ATM (0.45) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1337083 | 0.85 | ATM (0.45) | ATMACEMMEVHLMEN1 | |
| SCHEMBL1336059 | 0.85 | ATM (0.45) | ATMACEMMEVHLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8203003-B2 | 4-fluoropyrrolidine-2-carbonyl fluoride compounds and their preparative methods | UBE INDUSTRIES, LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20110275833-A1 | Novel 4-Fluoropyrrolidine-2-Carbonyl Fluoride Compounds and Their Preparative Methods | UBE INDUSTRIES, LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| WO-2010081014-A1 | NOVEL 4-FLUOROPYRROLIDINE-2-CARBONYL FLUORIDE COMPOUNDS AND THEIR PREPARATIVE METHODS | IM&T RESEARCH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275833-A1 | Novel 4-Fluoropyrrolidine-2-Carbonyl Fluoride Compounds and Their Preparative Methods | PFAS, AFF4, PAICS | ATM 4472/4885ACE 1878/4885MME 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.